Compounders Research Compare

Greenwich LifeSciences, Inc.(GLSI)

Biotechnology · Stafford, TX

$15.79-1.12 (-6.62%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

Stafford, TX

13 employees

greenwichlifesciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Snehal S. Patel

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T21:46:50.316Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:46:50.316Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 231,768,904
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 8,876,353
TTM operating EBITDA · period ending 2026-06-30: -21,865,253

FMP input reference: b6268879a98e6c39cef7c3f9e2e80a63ea5355fd191f52e510f01db01fc6dd59

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

GLSI EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

GLSI Competitors' EV/EBITDA Ratio

Greenwich LifeSciences, Inc.

Current

Market Cap

$231.77M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MacroGenics, Inc.

Market Cap

$231.37M

EV/EBITDA Ratio

N/A

TTM Avg

133.55x

3Y Avg

183129.66x

5Y Avg

183129.66x

InflaRx N.V.

Market Cap

$232.72M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Utah Medical Products, Inc.

Market Cap

$235.08M

EV/EBITDA Ratio

18.54x

TTM Avg

9.66x

3Y Avg

8.05x

5Y Avg

8.98x

Vogenx Inc.

Market Cap

$227.91M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Akebia Therapeutics, Inc.

Market Cap

$235.66M

EV/EBITDA Ratio

N/A

TTM Avg

21.13x

3Y Avg

83.14x

5Y Avg

83.14x

Biodesix, Inc.

Market Cap

$227.60M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SIGA Technologies, Inc.

Market Cap

$235.97M

EV/EBITDA Ratio

N/A

TTM Avg

5.07x

3Y Avg

4.97x

5Y Avg

6.62x

BioAge Labs Inc.

Market Cap

$236.82M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Invivyd, Inc.

Market Cap

$237.57M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Greenwich LifeSciences, Inc. (GLSI)	$231.77M	N/A	N/A	N/A	N/A
MacroGenics, Inc. (MGNX)vs ›	$231.37M	N/A	133.55x	183129.66x	183129.66x
InflaRx N.V. (IFRX)vs ›	$232.72M	N/A	N/A	N/A	N/A
Utah Medical Products, Inc. (UTMD)vs ›	$235.08M	18.54x	9.66x	8.05x	8.98x
Vogenx Inc. (VOGX)vs ›	$227.91M	N/A	N/A	N/A	N/A
Akebia Therapeutics, Inc. (AKBA)vs ›	$235.66M	N/A	21.13x	83.14x	83.14x
Biodesix, Inc. (BDSX)vs ›	$227.60M	N/A	N/A	N/A	N/A
SIGA Technologies, Inc. (SIGA)vs ›	$235.97M	N/A	5.07x	4.97x	6.62x
BioAge Labs Inc. (BIOA)vs ›	$236.82M	N/A	N/A	N/A	N/A
Invivyd, Inc. (IVVD)vs ›	$237.57M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics